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Background: Trastuzumab was registered in 2000 for the treatment of metastatic breast cancer, both as monotherapy
and combination therapy with paclitaxel. In this prospective, non-interventional observation study, the 10-year
experience with trastuzumab in the routine management of HER2-positive breast cancer was reviewed.
Methods: Between 2000 and 2010, 1843 evaluable patients with advanced HER2-positive breast cancer were recruited
in 223 institutions across Germany. Patients were prospectively monitored for about one year. Additional information
on long-term outcomes, progression-free survival (PFS), and overall survival (OS) were retrieved at several follow-up
points. There were no restrictions with respect to diagnostic or therapeutic procedures. Patients were stratified into
three cohorts depending on the treatment regimen, i.e. trastuzumab monotherapy (n =228, 12%), trastuzumab
combined with chemotherapy (n =1346, 73%), or trastuzumab combined with endocrine therapy (n =269, 15%).
Results: Median age was 59.5 years with a proportion of 28% being older than 65 years. Over a maximum follow-up
period of more than 10 years, 1538 PFS events were documented in 83% of patients, resulting in an estimated median
PFS of 11.8 months. Median OS, based on recorded death in 64% of patients, amounted to 34.4 months, with 48%
(95% confidence intervals 45 – 50%) still alive after three years. The subgroup selected for a treatment combination with
endocrine drugs only had distinctly longer PFS and OS than the other two groups, achieving medians of 23.3 months
and 56.3 months, respectively. Median PFS and OS in elderly patients over 65 years of age was 11.4 months and 28.3
months, respectively. Adverse reactions, including cardiac toxicity, of severity grade 3 or 4 were rare.
Conclusions: The superior outcome of treatment strategies including trastuzumab in HER2 overexpressing breast
cancer, proven in pivotal studies, was confirmed in the management of advanced breast cancer in Germany in the
routine setting. Our data suggest a comparable clinical benefit of treatment with trastuzumab in elderly patients
(>65 years), who are typically under-represented in randomized clinical studies.
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Trastuzumab (Herceptin®) was registered in Germany in
2000 for the treatment of HER2-positive metastatic
breast cancer (MBC), either as single agent in pretreated
patients or as first-line therapy in combination with pac-
litaxel. The latter was based on a pivotal trial demon-
strating that the addition of the humanized antibody,
trastuzumab, to taxane led to improved clinical out-
comes including longer OS, compared with single-agent* Correspondence: christian.jackisch@sana.de
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unless otherwise stated.paclitaxel, despite a crossover rate of approximately 70%
[1]. As a result of subsequent phase III trials [2,3], tras-
tuzumab was registered in 2004 for use in combination
with docetaxel and in 2007 for use with aromatase inhib-
itors. Today, trastuzumab-based therapy is considered the
standard of care for adjuvant or palliative treatment of
HER2-positive breast cancer [4,5].
This observational study comprising almost 2000 pa-
tients reflects the full spectrum of trastuzumab use in
routine practice in metastatic or locally advanced breast
cancer (LABC), with a patient population distinctly dif-
ferent from that typically recruited in phase III clinical
trials, particularly with respect to age. Our objective wasl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Jackisch et al. BMC Cancer 2014, 14:924 Page 2 of 9
http://www.biomedcentral.com/1471-2407/14/924to assess patient characteristics and patterns of care dur-
ing a period of 10 years, and to compare the long-term
results with those achieved in the pivotal trials.
Methods
Patient population and methods of observation
This non-interventional observation study focused on
patients with advanced breast cancer (MBC or LABC),
fulfilling the selection criteria according to the registered
drug label for trastuzumab (Herceptin®) in Germany. All
types of pretreatments were acceptable. HER2 positivity
was usually defined as 3+ staining in immunochemistry
or a positive result of fluorescence in situ hybridization
(FISH) in case of 2+ staining. Patients were treated in
accordance with the routine practice of the respective
institution, and findings were prospectively documented
on standardized case report forms. There were no re-
strictions with respect to individual diagnostic and
therapeutic procedures after patient registration, namely
concerning the concurrent administration of other anti-
neoplastic agents. The patients’ course of disease and
treatment were closely monitored through data queries,
either until trastuzumab therapy stop for whatever rea-
son, or for a treatment period of at least 12 months.
Thereafter, key long-term data were regularly retrieved
by fax forms until the patient’s death. Adverse drug re-
actions (ADR), as defined in the case report form, were
recorded according to the regulations of the German
drug law. Physicians from hospitals or practices were
invited to participate, either during the whole study
period or only for parts of it. Database closure was
September 2012.
This was an observational study in which physicians’
choices were guided by drug registration status and
treatment guidelines (rather than the observation proto-
col). As the study was started prior to 2007, it was in
agreement with the German FSA Codex [6] and the
German Arzneimittelgesetz Amendment 12, there was
no need/requirement for ethics committee approval or
written informed consent. For non-interventional studies
started in 2007 or later, the FSA Codex asks for submis-
sion to the ethics committee and to the regulators. Fur-
thermore, in the European Union, clinical research has
to be performed according to the Directive 2001/20/EC
of the European Parliament and of the Council on the
approximation of the laws, regulations and administra-
tive provisions of the Member States relating to the im-
plementation of good clinical practice in the conduct of
clinical trials on medicinal products for human use dat-
ing from April 2001. This regulation differentiates be-
tween the requirements for “interventional” and “non-
interventional” studies. This observational study clearly
fulfills the criteria for “non-interventional” as defined in
Article 2, c.Endpoint evaluation and statistical aspects
Tumor regression and progressive disease (PD) was re-
corded as the best response achieved, based on standard
clinical procedures at the discretion of the investigators,
without formal requirement of objective remission con-
firmation. PFS and OS were calculated as the time from
the first trastuzumab administration to the respective
event. Surviving patients without PD were censored at
the last valid observation point. Safety data were col-
lected during the 12-month period of detailed documen-
tation, but events reported afterwards were also included
in the analysis.
Event-related endpoints were analyzed using the
Kaplan-Meier method, providing 95% confidence in-
tervals (CIs) for proportions at specific time points.
Univariate analysis of potential prognostic factors was
performed using the logrank test [7]. All prognostic
factors with an associated P value <0.1 in the univari-
ate analysis were included in a multivariate Cox pro-
portional hazards model [8]. By backward selection, all
‘unnecessary’ variables were removed step-by-step, so
that the final model only contained covariates with a
P value ≤0.05. Hazard ratios (HR) with 95% CIs were
retrieved from this model. Examination of the treat-
ment decision process was performed using standard
contingency table methods and logistic regression. All
statistical analyses were of exploratory nature, with no
adjustment of P values for multiplicity. The term “sig-
nificant” was used in case of P ≤0.05. All reported P
values are two-sided.
Results
Overall, 1914 documentation forms were obtained from
223 clinics and practices across Germany between 2000
and 2010. After exclusion of clearly ineligible cases
(mostly patient reports referring to adjuvant trastuzumab
treatment), 1843 patients with advanced HER2-positive
breast cancer remained for this analysis. Although trastu-
zumab was only approved for the treatment of metastatic
breast cancer at the time recruitment started, 10% of
patients suffered from non-metastatic, locally recurrent
disease. Most patients (1346; 73%) received the first
trastuzumab-based therapy along with cytotoxic treat-
ment. Overall, 269 (15%) patients received the antibody in
combination with endocrine therapy, while the remaining
228 (12%) patients received trastuzumab monotherapy.
Most results are presented separately for these subgroups.
Baseline characteristics
Table 1 shows the patient and tumor characteristics be-
fore start of trastuzumab treatment. A considerable
number of patients were elderly, with the proportion of
participants ≥65 years of age increasing from 27% in the
first four years of recruitment to 40% thereafter. In









Number of patients 228 (12%) 1346 (73%) 269 (15%) 1843 (100%)
Age
Median (range) [years] 59.8 (31 – 91) 58.8 (21 – 87) 61.8 (31 – 95) 59.5 (21 – 95)
>65 years 26% 26% 36% 28%
>70 years 16% 13% 20% 14%
ECOG performance status
0 29% 30% 37% 31%
1 56% 55% 51% 54%
2 13% 13% 11% 13%
3-4 2% 2% 1% 2%
Tumor grade
G1 2% 3% 5% 3%
G2 49% 42% 49% 44%
G3 49% 55% 46% 53%
M1 disease at primary diagnosis 24% 26% 28% 26%
Relapse-free interval, median [years] 2.0 2.2 2.6 2.2
Hormone receptor status*
Estrogen-receptor positive 41% 54% 84% 57%
Progesterone-receptor positive 34% 47% 68% 48%
At least one positive 44% 58% 87% 61%
Metastatic sites at onset of trastuzumab treatment
0 18% 7% 14% 10%
1 45% 42% 52% 44%
2 25% 33% 23% 31%
3 8% 13% 9% 12%
≥4 4% 5% 1% 4%
Organ site involvement
Liver 34% 45% 25% 41%
Lung 26% 34% 21% 31%
Bone 41% 45% 55% 46%
Central nervous system 8% 5% 2% 5%
Pleural effusion 9% 12% 9% 11%
Ascites 1% 2% 1% 1%
Other 20% 20% 19% 20%
Previous treatment
Radiotherapy 68% 63% 67% 64%
Adjuvant chemotherapy 62% 61% 54% 60%
Adjuvant endocrine therapy 30% 42% 60% 43%
Palliative chemotherapy 52% 36% 35% 38%
Palliative endocrine therapy 19% 28% 51% 30%
Received anthracycline and taxane 48% 37% 46% 40%
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Table 1 Patient and tumor characteristics (n =1843) (Continued)
Received trastuzumab 20% 7% 13% 9%
No. of previous palliative chemotherapy regimens (n =692**)
1 53% 56% 63% 57%
2 20% 24% 21% 23%
3 14% 10% 9% 11%
4 12% 8% 5% 8%
LVEF, median (range) [%] 65 (30 – 82) 65 (35 – 95) 65 (40 – 98) 65 (30 – 98)
* unknown in 5% of patients, ** population with palliative cytotoxic pretreatment.
Abbreviations: ECOG Eastern Cooperative Oncology Group, LVEF Left ventricular ejection fraction.
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ation with endocrine therapy were older and showed a
more favorable prognostic profile, i.e. a better perform-
ance status, less G3 tumors, a longer relapse-free inter-
val, fewer metastatic sites, a focus on bone rather than
visceral disease, less palliative pretreatment, and a positive
hormone receptor status. Women receiving trastuzumab
monotherapy were typically more heavily pretreated with
palliative chemotherapy. In this subgroup, 28% of patients
had previously undergone one regimen for advanced dis-
ease, while 11% of patients had received two and 14% of
patients three or more previous regimens for advanced
disease. No differences between treatment groups with re-
spect to baseline cardiac function were reported.
Treatment
In line with the limited period of detailed data recording,
median duration of documented trastuzumab treatment
amounted to almost exactly one year, since half of the
patients were reported to be treated for more than 52
weeks. However, median duration of the antibody ther-
apy without detection of tumor progression was 43
weeks only, indicating a trastuzumab treatment in mul-
tiple lines in a considerable number of patients (see
below). When including the follow-up information re-
ceived via fax transmission, median treatment duration
rose to 64 weeks overall (55 weeks in the monotherapy
subgroup, 62 weeks in the chemotherapy subgroup, and
98 weeks in the endocrine therapy subgroup). In total,
more than one third of the patients received trastuzu-
mab for more than two years. As the three-weekly
schedule became an alternative option to the initially ap-
proved weekly application only late during the observa-
tion study period, 64% of the patients received 2 mg/kg
body weight, and 28% of patients received 6 mg/kg.
(Due to the loading-dose strategy, these figures are based
on analysis of the second trastuzumab application).
Among the 1336 patients for whom the concomitant
cytotoxic regimen was known, 78% received only one
cytotoxic agent. Almost half of the patients (47%) receiveda taxane, predominantly paclitaxel. The other chemothera-
peutics frequently combined with trastuzumab were vino-
relbine (23%) and capecitabine (6%). Anthracyclines were
administered concurrently with trastuzumab in about 4%
of the patients in the chemotherapy subgroup.
The reasons for using trastuzumab in combination
with cytotoxic agents were studied in further detail. In
the univariate analysis, age ≤65 years (P =0.033), nega-
tive hormone receptor status (P =0.0012), two or more
sites of metastasis (P <0.0001), and visceral metastasis
(P <0.0001) were significantly associated with the deci-
sion to administer chemotherapy together with trastuzu-
mab. In contrast, the relapse-free interval, stage IV
disease at presentation, and CNS metastases had no
major impact on this decision. In a multivariate logistic re-
gression model, hormone receptor status (P =0.00064)
and visceral metastases (P <0.0001) remained highly sig-
nificant independent predictors.
Efficacy
In the 1737 patients evaluable for response, complete re-
mission (CR) was reported in 263 (15%) patients and
partial remission (PR) in 743 (43%) patients. A further
523 (30%) patients experienced stable disease, whereas
12% showed signs of primary PD. This resulted in an
overall response rate (ORR) of 58% (95% CIs 56 to 60%).
ORR was highest in the subgroup receiving trastuzumab
together with chemotherapy (60%). In the subgroups re-
ceiving trastuzumab monotherapy or trastuzumab com-
bined with endocrine treatment, ORRs amounted to 44%
and 40%, respectively. In patients with chemotherapeutic
pre-treatment for advanced disease, ORR was lower
(53%). The same holds true for patients having previ-
ously received both anthracyclines and taxanes (adjuvant
or palliative; ORR =51%).
So far, 1538 PFS events (83%) and 1174 deaths (64%)
have been recorded in the database, with a maximum
follow-up period of more than 10 years. Figure 1A shows
PFS for the whole study population (median: 11.8
months, 95% CIs 11.1 to 12.6 months), and Figure 1B
Figure 1 Progression-free survival in the total patient population (A) and the various subgroups (B).
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(median: 15.4%), chemotherapy (11.0 months), and endo-
crine therapy (23.3 months), clearly documenting the ra-
tionale of treatment choice depending on prognostic
factors. After two years, PFS rates were 30% overall (95%
CIs 28 to 32%), and 39%, 25%, and 49% in the respective
subgroups. There were no major differences with respect
to median PFS depending on the type of concomitant
chemotherapy chosen (11.5 and 10.8 months for taxane
and vinorelbine, respectively, and 10.3 months in patients
selected for polychemotherapy).
Figure 2 shows OS based on 1174 (64%) reported
deaths for the whole population and the subpopulations.
Overall median survival amounted to 34.4 months (95%
CIs 33.2 to 36.1 months), with 48% (95% CIs 45 to 50%)
still living after three years. Because of the criteriaapplied when selecting the patients’ treatment, median
survival was considerably shorter in patients simultan-
eously treated with chemotherapy (31.9 months) than
those undergoing monotherapy with trastuzumab (42.8
months) or those receiving trastuzumab combined with
endocrine therapy (56.3 months). Three-year survival rates
were 43%, 55%, and 66%, respectively.
Prognostic factors for long-term results
The impact of several prognostic characteristics on PFS
and OS was analyzed, focusing on the subgroup of patients
receiving trastuzumab in combination with chemotherapy,
in order to achieve homogeneity and avoid interactions be-
tween baseline factors and treatment decision (Table 2).
PFS was significantly longer in patients without previous
chemotherapy for advanced disease (median, 11.8 vs. 9.5
Figure 2 Overall survival in the total patient population (A) and the various subgroups (B).
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and with stage IV disease at presentation (13.1 vs. 10.1
months). No major prognostic impact was detected for hor-
mone receptor status or age, with medians of 10.7 months
and 11.4 months in the cohorts aged ≤65 years and >65
years, respectively. In a multivariate Cox model, bones as
the sole metastatic site and stage IV at presentation
remained the only independent significant factors.
With respect to OS, previous cytotoxic therapy for ad-
vanced disease (median, 27.4 vs. 34.6 months), age >65
years (28.3 vs. 33.4 months), bone lesions only (41.0 vs.
30.0 months), hormone receptor positivity (33.2 vs. 29.4
months), and stage IV at presentation (34.8 vs. 31.4
months) showed a correlation of at least borderline sig-
nificance. In the regression model, age, bone lesionsonly, and stage IV disease retained the conventional sig-
nificance level.
Among the total patient population, 90 patients with
CNS metastases were identified, exhibiting distinctly
shorter PFS (median, 7.5 vs. 12.0 months, P <0.0001)
and OS (median, 20.3 vs. 34.8 months, P <0.0001).Trastuzumab treatment beyond progression
Among the patients entering the study while undergoing
first-line treatment for advanced disease, 418 women ful-
filled the criteria for an analysis of treatment beyond
progression and its impact on the course of disease.
Both univariate and multivariate analyses suggested dis-
tinctly longer survival in the 261 patients with continued
Table 2 Univariate and multivariate analysis of prognostic factors for progression-free survival and overall survival
Parameter Progression-free survival Overall survival
Univariate p Multivariate p Univariate p Multivariate p
Palliative cytotoxic pretreatment 0.00051 – < 0.0001 –
Age >65 years – – 0.072 0.038
Metastases other than skeletal 0.0061 0.032 0.0041 0.016
Hormone-receptor negative – – 0.039 –
M0 at initial diagnosis 0.0071 0.0013 0.040 0.0046
– denotes p >0.1.
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separate publication [9].
Safety
Trastuzumab was well tolerated with predictable and
manageable ADR both when given as monotherapy and
in combination with other treatments. Table 3 presents
the National Cancer Institute Common Toxicity Criteria
[NCI CTC] grade 3/4 ADR with an incidence of ≥1% in
the total population by subgroups. The most common
grade 3/4 ADR was leukopenia with a frequency of 5%,
but this was only observed in the chemotherapy sub-
group. Cardiac toxicity occurred with an incidence of
2.3% across all severity grades. Grade 3 ADR occurred in
0.5% (no grade 4 event). However, this proportion was
distinctly lower in patients aged <65 years than in the
older patients (1.5% vs. 4.2%).
Discussion and conclusions
This observation study evaluated the use of trastuzumab
in advanced HER2-positive breast cancer since its regis-
tration in 2000, based on the experience in a representa-
tive selection of more than 200 clinics and practices in
Germany outside the setting of a prospective interven-
tional clinical trial. To the best of our knowledge, our
data represents information on the longest follow-upTable 3 Frequency of adverse drug reactions of grade 3/4




Patients with NCI CTC grade [n (%)]
T* T + CT** T + HT*** Total
Hematological
Hemoglobin decreased - 13 (1%) - 13 (1%)
WBC decreased 1 (0%) 57 (4%) - 58 (3%)
Granulocytes decreased 1 (0%) 16 (1%) 1 (0%) 18 (1%)
Non-hematological
Dyspnea 1 (0%) 18 (1%) 1 (0%) 20 (1%)
Pain 2 (1%) 16 (1%) 3 (1%) 21 (1%)
*trastuzumab monotherapy, **trastuzumab plus chemotherapy,
***trastuzumab plus endocrine therapy only.
NCI CTC: National Cancer Institute Common Toxicity Criteria; WBC: white
blood cells.period reported on trastuzumab treatment in this set-
ting. Moreover, the study provides important data on the
use, efficacy, and safety of trastuzumab under “real-life”
conditions in a large patient cohort.
When comparing our data with those obtained from
the pivotal studies that typically involve selected target
groups, a striking difference with respect to age distribu-
tion is apparent. In the registration study by Slamon
et al. [1], mean and median age was 53 years, with mean
ages in subsequent randomized studies ranging from 54
to 56 years [2,3,10,11]. Thus, the patients participating
in the randomized trials were considerably younger than
those assessed in the present study (median age of al-
most 60 years). Even the French HERMINE study that
retrospectively selected a cohort from 2002, included pa-
tients with a lower median age, i.e. 54 years [12]. Simi-
larly, only 21% of the 1001 patients participating in the
US-based observational registHER study between 2003
and 2006, were beyond the age of 65 years, as reported
in a recent publication focusing on elderly patients [13].
The increasing numbers of elderly patients treated with
trastuzumab in more recent years is thought to be the
result of the growing clinical experience with the use of
this antibody. In our study, the proportion of patients
aged 65 years or more increased from 27% (by 2003) to
39% in the period thereafter.
Although earlier clinical trials and the present observa-
tional study differ in a number of respects, our results
confirm the favorable outcomes reported in the pivotal
studies. The high ORR may partly be due to some limi-
tations with respect to defined response criteria and re-
quirement of remission confirmation. However, the
median PFS of almost one year in the overall population
and the chemotherapy/trastuzumab subgroup compares
well with data published from interventional studies on
taxane/trastuzumab regimens [14]. In the paclitaxel sub-
group of the initial registration study (HO648g) by
Slamon et al., the lower median PFS of 6.9 months may
be explained by the inclusion of patients with HER2
overexpression of 2+ only [1]. The more recent studies
involving trastuzumab combined with docetaxel [2,11]
reported PFS values of 11.7 and 12.4 months, respect-
ively, which are very similar to ours. The same applies to
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ment with paclitaxel combined with trastuzumab [15].
Translation of the beneficial results from clinical trials
into routine practice is even more convincingly shown
with respect to OS where a median of about 34.5
months (both in the total population and the chemo-
therapy/trastuzumab subgroup) was achieved. Again, in
the HO648g study, median OS was somewhat lower
(25.1 months), but our results are in good agreement
with medians for combinations with docetaxel (31.2
months and 35.7 months) and vinorelbine (38.8 months)
[2,11]. Nevertheless, when comparing our results to the
pivotal studies, one clearly has to acknowledge the limi-
tation of a possible data collection bias. In particular, we
have no access to data from those patients, which were
not assigned to trastuzumab treatment in spite of a posi-
tive HER2 status. Moreover, the selection process has
certainly changed a lot during the ten year study period.
In MBC the additional option of using a dual blockade
in HER2 overexpressing endocrine sensitive breast can-
cer (Her2+/ER+) was not widely implemented in the
routine setting in Germany during our study period. The
combination of endocrine therapy plus trastuzumab
without chemotherapy was used in 15%, only. Interest-
ingly this option was widely used in the elderly women
(Table 1). However, in our routine setting, the risk-
adapted selection of patients for endocrine therapy in
combination with trastuzumab resulted in an exception-
ally long median OS of almost 5 years. The importance
of the correct patient selection was clearly shown in the
two randomized studies with trastuzumab/endocrine
drug combinations, for which distinctly different PFS re-
sults (i.e. 4.8 months and 14.1 months) were reported
[3,16]. In summary, the option to combine aromatase
inhibitors either with trastuzumab or lapatinib in those
individuals not being an ideal candidate for a chemo-
therapy bases regime seems to be a perfect and well
tolerated option in controlling this subtype of MBC.
Likewise, the favorable long-term data obtained for the
trastuzumab monotherapy group in our observational
study contrasts with published data on trastuzumab
monotherapy in the US or German compassionate-use
trials. There, PFS medians of only 3 to 5 months were
achieved [17-19]. Thus, the careful selection of patients
with a relatively low metastatic burden or even locore-
gional disease, in our cohort appears to be responsible
for the favorable outcome in this subgroup.
The outcome of trastuzumab treatment in elderly pa-
tients with advanced breast cancer has been specifically
addressed in the registHER study [13]. Both their and
our data show no inferior results for patients ≥65 vs.
<65 years in median PFS (11.7 vs. 11.0 months, and 11.4
vs. 10.7 months, respectively). However, the correspond-
ing OS data show some difference, again uniformly inboth studies, with 31.2 vs. 40.4 months, and 28.3 vs. 33.4
months, respectively. This may be due, in part, to more
deaths not related to breast cancer in the older patient
group. As described elsewhere [9], we were able to
analyze trastuzumab treatment beyond progression in a
rather large subpopulation (n = 418), confirming the fa-
vorable outcome reported in the randomized study [20].
It is of special importance that despite the large num-
ber of patients included in the present observational
study, no major new safety issues emerged. The low fre-
quency of ADR points to an underreporting, which is a
clear limitation of the observational study design. In the
subgroup receiving trastuzumab combined with chemo-
therapy, toxic effects were more likely assigned to the
chemotherapy than to trastuzumab. Significant cardiac
problems occurred very rarely, albeit with an expected
higher frequency in elderly patients.
Recent developments have greatly expanded the arma-
mentarium of drugs targeting HER2-positive breast cancer
[21]. This includes the pharmacokinetically bioequivalent
option of subcutaneous administration of trastuzumab,
which is strongly preferred by the patients [22], and a
first antibody-cytotoxic conjugate, emtansine, highly active
after trastuzumab pre-treatment [23,24]. Moreover, the
tyrosine kinase inhibitor lapatinib in second-line combina-
tions, namely with simultaneous trastuzumab [25], and
the synergistically efficacious combination of trastuzumab
and pertuzumab [26] constitute valuable alternatives.
These findings confirm, for the time being, trastuzu-
mab remains the essential cornerstone of any routine
treatment strategy in HER2-positive breast cancer.
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